Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Ascletis"

12 News Found

Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing
Diagnostic Center | July 04, 2022

Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection

China NMPA approves phase II clinical trial of ASC40
Policy | August 09, 2021

China NMPA approves phase II clinical trial of ASC40

Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne

Latest Stories

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

Roche secures CE mark for Accu-Chek SmartGuide CGM with mySugr app integration

Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging